Alligator Bioscience AB (publ) (ATORX.ST)
SEK 0.27
(-3.79%)
SEK 0.27
(-3.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 58.1 Million SEK | 62.78% |
| 2022 | 35.69 Million SEK | 175.79% |
| 2021 | 12.94 Million SEK | 197.4% |
| 2020 | 4.35 Million SEK | -0.14% |
| 2019 | 4.35 Million SEK | -83.83% |
| 2018 | 26.95 Million SEK | -52.6% |
| 2017 | 56.87 Million SEK | -2.34% |
| 2016 | 58.24 Million SEK | -79.9% |
| 2015 | 289.79 Million SEK | 23384.36% |
| 2014 | 1.23 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.57 Million SEK | 8.6% |
| 2024 Q3 | 1.43 Million SEK | -81.07% |
| 2024 Q1 | 6.97 Million SEK | -40.56% |
| 2023 Q3 | 19.41 Million SEK | 11.82% |
| 2023 Q2 | 17.36 Million SEK | 80.99% |
| 2023 FY | 58.1 Million SEK | 62.78% |
| 2023 Q1 | 9.59 Million SEK | -52.18% |
| 2023 Q4 | 11.73 Million SEK | -39.54% |
| 2022 Q1 | 5.35 Million SEK | 2.04% |
| 2022 FY | 35.69 Million SEK | 175.79% |
| 2022 Q4 | 20.06 Million SEK | 292.74% |
| 2022 Q3 | 5.1 Million SEK | -1.2% |
| 2022 Q2 | 5.17 Million SEK | -3.47% |
| 2021 FY | 12.94 Million SEK | 197.4% |
| 2021 Q2 | 3.77 Million SEK | 512.16% |
| 2021 Q3 | 3.3 Million SEK | -12.63% |
| 2021 Q4 | 5.24 Million SEK | 59.06% |
| 2021 Q1 | 617 Thousand SEK | 271.69% |
| 2020 Q2 | 4.35 Million SEK | 0.0% |
| 2020 Q3 | 280 Thousand SEK | -93.57% |
| 2020 FY | 4.35 Million SEK | -0.14% |
| 2020 Q4 | 166 Thousand SEK | -40.71% |
| 2020 Q1 | - SEK | 100.0% |
| 2019 Q2 | 30 Thousand SEK | -25.0% |
| 2019 FY | 4.35 Million SEK | -83.83% |
| 2019 Q4 | -1000.00 SEK | -100.02% |
| 2019 Q3 | 4.28 Million SEK | 14193.33% |
| 2019 Q1 | 40 Thousand SEK | -99.84% |
| 2018 Q3 | 197 Thousand SEK | -49.74% |
| 2018 Q4 | 25.62 Million SEK | 12908.12% |
| 2018 Q1 | 776 Thousand SEK | -98.49% |
| 2018 FY | 26.95 Million SEK | -52.6% |
| 2018 Q2 | 392 Thousand SEK | -49.48% |
| 2017 Q3 | 1.77 Million SEK | 37.96% |
| 2017 FY | 56.87 Million SEK | -2.34% |
| 2017 Q1 | 2.52 Million SEK | -60.78% |
| 2017 Q2 | 1.28 Million SEK | -49.15% |
| 2017 Q4 | 51.29 Million SEK | 2798.25% |
| 2016 Q2 | 3.78 Million SEK | -91.27% |
| 2016 Q1 | 43.36 Million SEK | 8385.32% |
| 2016 FY | 58.24 Million SEK | -79.9% |
| 2016 Q4 | 6.43 Million SEK | 38.02% |
| 2016 Q3 | 4.66 Million SEK | 23.08% |
| 2015 FY | 289.79 Million SEK | 23384.36% |
| 2015 Q3 | 289.28 Million SEK | 0.0% |
| 2015 Q4 | 511 Thousand SEK | -99.82% |
| 2014 FY | 1.23 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ziccum AB (publ) | 3.74 Million SEK | -1450.761% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 90.567% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -15.098% |
| Mendus AB (publ) | 28.48 Million SEK | -103.977% |
| Genovis AB (publ.) | 158.23 Million SEK | 63.277% |
| Intervacc AB (publ) | 8.01 Million SEK | -624.978% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -1228.464% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 65.908% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -32.374% |
| Aptahem AB (publ) | 2.63 Million SEK | -2108.847% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -5514.203% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -75363.636% |
| Fluicell AB (publ) | 3.33 Million SEK | -1640.773% |
| Saniona AB (publ) | 16.84 Million SEK | -245.053% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -254.16% |
| Biovica International AB (publ) | 7.29 Million SEK | -697.078% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -4730.175% |
| AcouSort AB (publ) | 10.55 Million SEK | -450.725% |
| Xintela AB (publ) | 78 Thousand SEK | -74396.154% |
| Abliva AB (publ) | 137 Thousand SEK | -42313.869% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -0.88% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -2785.154% |
| OncoZenge AB (publ) | 3000.00 SEK | -1936800.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -37388.387% |
| CombiGene AB (publ) | 5.54 Million SEK | -948.084% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 95.185% |
| Camurus AB (publ) | 1.71 Billion SEK | 96.615% |
| Corline Biomedical AB | 25.03 Million SEK | -132.149% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -923.371% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -7959.223% |
| I-Tech AB | 120.86 Million SEK | 51.922% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 56.667% |
| Cyxone AB (publ) | 5.14 Million SEK | -1028.73% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -724.213% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -444.854% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -417.424% |
| Nanologica AB (publ) | 1.44 Million SEK | -3926.819% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -109535.849% |
| BioInvent International AB (publ) | 71.46 Million SEK | 18.687% |
| Alzinova AB (publ) | 270 Thousand SEK | -21421.111% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -64.983% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -3871.716% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -1959.072% |
| Simris Alg AB (publ) | 4.35 Million SEK | -1234.566% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -44597.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 75.66% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -252539.13% |